Kyongbo Pharma says court stays product approval cancellations pending appeal ruling

Bitget2026/09/30 05:58

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Kyongbo Pharmaceutical disclosed a court-ordered stay on the effectiveness of product license cancellations tied to its business suspension case.
The stay runs until 30 days after an appellate ruling in the main lawsuit seeking to overturn the license-cancellation measure.
The suspension-related affected sales were KRW 13.48 billion, equal to 5.65% of 2024 revenue of KRW 238.56 billion.
The license cancellations had been set to take effect from June 24, 2025.
The company plans to update disclosures depending on the appellate court’s decision on the merits.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyongbo Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260930000336), on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Kyongbo Pharma says court stays product approval cancellations pending appeal ruling

You may also like

Crypto prices